Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome

doi:10.1007/s00277-001-0391-x

Paper

Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome

Published 2001 · A. Takami, H. Asakura, S. Nakao

Annals of Hematology

Q1 SJR score

14

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract. Vitamin K2 induces differentiation of leukemic cell lines and apoptosis of immature blasts in myelodysplastic syndrome (MDS). We recently reported a case of MDS-refractory anemia (MDS-RA) with trilineage hematologic response to oral administration of menatetrenone, a vitamin K2 analog. To determine a possible role of this agent in treatment of MDS-RA, we conducted a prospective randomized trial assessing the safety and efficacy of menatetrenone. A total of 18 consecutive patients newly diagnosed with MDS-RA were randomized to receive either 45 mg of oral menatetrenone (group 1) or no menatetrenone (group 2). Administration of menatetrenone was well tolerated. Of the nine patients in group 1 (56%), five improved with menatetrenone treatment while only one (11%) of the group 2 patients improved. Three patients (33%) showed a major response in absolute neutrophil count (ANC), two (22%) showed a major response in hemoglobin concentration, and two of the nine (22%) showed a major response in platelet count. The ANC of group 1 patients rose after treatment, while that of group 2 patients decreased slightly at follow-up after 16 weeks (p=0.03). Significant improvement was also seen in final platelet count (p=0.01), but not in hemoglobin concentration. Given the absence of toxicity, menatetrenone can be recommended for all patients with MDS-RA.

RCT

Study Snapshot

Menatetrenone, a vitamin K2 analog, effectively improves cytopenia in patients with myelodysplastic syndrome-refractory anemia, making it a safe and recommended treatment option.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome

Sign up to use Study Snapshot

References

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Standardized response criteria for myelodysplastic syndromes (MDS) clinical trials are essential for ensuring comparability and improving communication among investigators.

Vitamin K2 (Menatetrenone) Effectively Prevents Fractures and Sustains Lumbar Bone Mineral Density in Osteoporosis

Vitamin K2 treatment effectively prevents new fractures in osteoporosis patients, but does not increase lumbar bone mineral density.

Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2.7 monoclonal antibody

Vitamin K2 effectively induces apoptosis of leukemic blast cells in myelodysplastic syndrome patients, suggesting potential for treatment of blastic transformation.

Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid

Vitamin K2 and its derivatives can induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid, suggesting potential for treatment of myelogenous leukemias.

Vitamin K-dependent carboxylase: mRNA distribution and effects of vitamin K-deficiency and warfarin treatment.

Warfarin treatment and fasting in rats increase liver carboxylase activity through a posttranscriptional mechanism, rather than affecting transcription.

Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).

Combination chemotherapy can achieve more than 50% complete remission in patients with poor prognosis MDS and AML, but maintaining remission after remission-induction therapy is challenging.

The growth inhibitory effects of vitamins K and their actions on gene expression

Vitamins K1, K2, and K3 suppress immature prothrombin secretion and inhibit growth of hepatocellular carcinoma cells, with a novel growth inhibitory mechanism possibly involving carboxylation.

Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines.

Vitamin K2 effectively induces differentiation in various human myeloid leukemia cell lines, suggesting its potential use in differentiation therapy in combination with other inducers.

Proposals for the classification of the myelodysplastic syndromes

New diagnostic criteria for myelodysplastic syndromes (MDS) are proposed, focusing on blast cell proportions in peripheral blood and bone marrow, and may help interpret data from cytogenetic and bone marrow culture studies.

Citations